Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 01:39PM ET
6.49
Dollar change
+0.33
Percentage change
5.36
%
IndexRUT P/E- EPS (ttm)-1.27 Insider Own38.75% Shs Outstand64.58M Perf Week-0.92%
Market Cap419.58M Forward P/E- EPS next Y-1.39 Insider Trans0.00% Shs Float39.60M Perf Month-13.35%
Income-90.21M PEG- EPS next Q-0.34 Inst Own76.31% Short Float10.67% Perf Quarter-3.13%
Sales0.00M P/S- EPS this Y-8.65% Inst Trans32.55% Short Ratio5.16 Perf Half Y35.21%
Book/sh3.95 P/B1.64 EPS next Y-1.03% ROA-32.48% Short Interest4.23M Perf Year-39.29%
Cash/sh4.07 P/C1.59 EPS next 5Y- ROE-33.89% 52W Range3.26 - 14.04 Perf YTD0.00%
Dividend Est.- P/FCF- EPS past 5Y-12.40% ROI-35.33% 52W High-53.79% Beta-0.66
Dividend TTM- Quick Ratio22.39 Sales past 5Y-20.00% Gross Margin- 52W Low99.08% ATR (14)0.61
Dividend Ex-Date- Current Ratio22.39 EPS Y/Y TTM30.50% Oper. Margin0.00% RSI (14)46.56 Volatility6.71% 9.18%
Employees66 Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom1.50 Target Price14.21
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-0.45% Payout- Rel Volume1.60 Prev Close6.16
Sales Surprise- EPS Surprise1.09% Sales Q/Q- EarningsMar 14 AMC Avg Volume818.86K Price6.49
SMA20-6.98% SMA50-1.20% SMA2002.01% Trades Volume861,086 Change5.36%
Date Action Analyst Rating Change Price Target Change
Jun-22-23Initiated Mizuho Buy $16
Jun-07-23Initiated Jefferies Buy $18
May-31-23Initiated ROTH MKM Buy $23
May-08-23Initiated BMO Capital Markets Outperform $18
Feb-14-23Initiated JMP Securities Mkt Outperform $17
Feb-07-23Initiated UBS Buy $19
Sep-12-22Initiated H.C. Wainwright Neutral $6
Sep-14-21Resumed Goldman Buy $21
Mar-02-21Initiated JP Morgan Overweight $32
Mar-02-21Initiated Goldman Buy $29
Mar-14-24 04:05PM
Mar-11-24 04:05PM
Mar-07-24 04:05PM
Feb-27-24 04:05PM
Feb-07-24 04:05PM
08:05AM Loading…
08:05AM
Feb-02-24 04:05PM
Jan-04-24 04:05PM
Jan-03-24 04:05PM
Nov-29-23 04:05PM
Nov-27-23 04:05PM
Nov-14-23 12:16PM
08:05AM
Nov-13-23 08:05AM
Nov-09-23 08:05AM
04:05PM Loading…
Nov-03-23 04:05PM
Nov-02-23 04:05PM
Oct-19-23 04:05PM
Oct-16-23 08:05AM
Oct-03-23 04:05PM
Sep-06-23 04:05PM
Sep-05-23 04:05PM
Aug-08-23 04:15PM
04:05PM
Aug-03-23 06:00PM
05:05PM
Jul-28-23 07:01PM
Jul-18-23 04:05PM
Jul-05-23 04:05PM
Jun-26-23 04:05PM
04:30PM Loading…
Jun-06-23 04:30PM
Jun-02-23 04:05PM
May-28-23 09:45AM
May-25-23 05:05PM
May-24-23 04:05PM
May-22-23 04:05PM
May-15-23 08:05AM
May-09-23 04:05PM
May-03-23 04:05PM
Apr-25-23 12:00PM
Mar-30-23 02:28PM
Mar-27-23 04:05PM
08:05AM
Mar-08-23 05:26AM
Mar-02-23 04:05PM
Feb-26-23 10:51AM
Feb-08-23 12:00PM
Feb-02-23 04:05PM
Jan-12-23 04:05PM
Jan-05-23 04:05PM
Dec-23-22 04:05PM
Dec-20-22 07:40PM
08:05AM
Dec-19-22 04:31PM
Dec-01-22 04:05PM
Nov-16-22 09:31AM
Nov-09-22 04:05PM
Nov-04-22 08:05AM
Oct-26-22 04:05PM
Oct-12-22 05:26AM
Oct-11-22 04:05PM
Sep-29-22 06:03AM
Sep-21-22 05:33AM
Sep-07-22 04:05PM
Aug-19-22 06:50AM
Aug-12-22 08:00AM
Aug-08-22 04:05PM
Jul-27-22 04:05PM
Jul-22-22 12:00PM
Jun-22-22 04:05PM
Jun-09-22 06:31AM
Jun-08-22 04:05PM
Jun-01-22 04:05PM
May-16-22 04:05PM
Apr-05-22 01:38PM
Apr-04-22 04:05PM
Mar-21-22 04:05PM
Mar-03-22 04:05PM
Feb-28-22 04:05PM
Feb-04-22 11:37AM
Feb-02-22 05:38PM
Jan-06-22 07:05AM
Jan-03-22 04:05PM
Nov-15-21 04:05PM
Nov-12-21 07:05AM
Nov-10-21 07:17AM
Nov-09-21 04:05PM
Nov-03-21 02:52PM
Oct-18-21 04:05PM
Oct-05-21 04:05PM
Oct-04-21 08:38AM
Sep-28-21 04:05PM
Sep-15-21 06:07PM
Sep-08-21 07:05AM
Sep-02-21 04:05PM
Aug-16-21 04:05PM
Aug-03-21 04:05PM
Jun-24-21 04:05PM
Jun-14-21 12:41PM
07:05AM
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.